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Abstract The objective of the present study was to
review previous investigations on the association of hap-
lotypes in the G-protein b3 subunit (GNB3) gene with
representative cardiovascular risk factors/phenotypes:
hypertension, overweight, and variation in the systolic and
diastolic blood pressures (SBP and DBP, respectively) and
as well as body mass index (BMI). A comprehensive lit-
erature search was undertaken in Pubmed, Web of Science,
EMBASE, Biological Abstracts, LILACS and Google
Scholar to identify potentially relevant articles published
up to April 2011. Six genetic association studies encom-
passing 16,068 participants were identified. Individual
participant data were obtained for all studies. The three
most investigated GNB3 polymorphisms (G-350A, C825T
and C1429T) were considered. Expectation–maximization
and generalized linear models were employed to estimate
haplotypic effects from data with uncertain phase while
adjusting for covariates. Study-specific results were com-
bined through a random-effects multivariate meta-analysis.
After carefully adjustments for relevant confounding fac-
tors, our analysis failed to support a role for GNB3 hap-
lotypes in any of the investigated phenotypes. Sensitivity
analyses excluding studies violating Hardy–Weinberg
expectations, considering gender-specific effects or more
extreme phenotypes (e.g. obesity only) as well as a fixed-
effects ‘‘pooled’’ analysis also did not disclose a significant
influence of GNB3 haplotypes on cardiovascular pheno-
types. We conclude that the previous cumulative evidence
does not support the proposal that haplotypes formed by
common GNB3 polymorphisms might contribute either to
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the development of hypertension and obesity, or to the
variation in the SBP, DBP and BMI.
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Introduction
The guanine nucleotide-binding protein subunit b3 con-
stitutes a major component of the heterodimeric G-pro-
teins, which in turn act as signaling switches by integrating
extracellular signals from ligand-activated G-protein-cou-
pled receptors to downstream effectors [1]. Polymorphisms
in the GNB3 (chromosome 12p) have been associated with
essential hypertension (EH) and obesity [2, 3], but there is
evidence for statistical heterogeneity (i.e. variation in effect
estimates beyond chance) [2]. Thus, a major question so far
has been whether these polymorphisms display a genuine
effect when considered individually, or whether they might
modulate the risk of hypertension/obesity when only cer-
tain variants are co-inherited (e.g. cis–trans effects, in
which the genetic effect would be only observed when
markers are considered collectively). Indeed, the ubiqui-
tous role of multi-marker effects [4, 5] and the importance
of contrasting candidate polymorphisms against the back-
ground of other gene variants have been documented in the
literature recently [4–7]. In this respect, some investigators
claim that haplotypes might exhibit a more prominent role
in complex diseases such as hypertension and obesity [8–
10]. The logic behind this statement stems from the fact
that single-marker based analyses may be less powerful
because a large amount of information contained in
flanking regions of a genotyped marker is ignored. As a
result, a more robust strategy would be a meta-analysis of
haplotypes, which captures not only genetic information
from different markers [6] but also data across independent
studies [11]. Following these rationale, we conducted a
review of previous studies on the association of haplotypes
in the GNB3 gene with representative cardiovascular risk
factors: hypertension, overweight, and variation in the
systolic and diastolic blood pressures (SBP and DBP,
respectively) and as well as BMI. Contrary to most meta-
analyses, individual participant data were obtained for all
studies, allowing us to present the results of individual
studies adjusted for the same confounding factors. In
addition, these data were used in a carefully conducted
random-effects multivariate meta-analysis in an attempt to
increase statistical power.
Materials and methods
Eligibility criteria
Studies (i) investigating the association of two or more
GNB3 polymorphism either with blood pressure related-
phenotypes (e.g. EH, SBP and DBP), (ii) or with adiposity-
related traits (e.g. obesity, overweight, and BMI as a con-
tinuous trait), (iii) involving unrelated subjects and (iv)
using validated methods of genotyping were considered
eligible for the present meta-analysis.
Searches for potential studies were carried out using
keywords described in detail elsewhere [2] as well as
personal contact with experts in the field. The following
databases (from inception through 01 April, 2011) were
screened: Pubmed, Web of Science, EMBASE, Biological
Abstracts, LILACS and Google Scholar. No restriction was
imposed on (i) language of publication, (ii) ancestry of the
examined population, (iii) original criteria used to define
the presence of hypertension/obesity and (iv) publication
status (published or unpublished).
Data collection and management
The corresponding author of each eligible study was con-
tacted electronically with a project proposal and requests to
provide individual-participant data. The following data
were obtained from all studies: list of coding schemes and
units, age, gender, SBP, DBP, BMI (in kg/m2), use of
antihypertensive medications, and genetic data for the
investigated polymorphisms. Whenever available, data on
lipids, presence of diabetes, and other important covariates
were also obtained and included in sensitivity analyses.
Data cleaning and standardization were performed in a
single center to avoid potential center-specific biases. All
studies were approved by the local ethical committees
following the procedures of each country.
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Genetic markers
Table 1 presents the three GNB3 polymorphisms investi-
gated. These markers were chosen on the basis on their
relative importance in expression assays as well as the
available cumulative evidence (e.g. these markers are the
most investigated GNB3 polymorphisms). Genotypes were
scored by different genotyping technologies, but the
accuracy of each method has been tested by a number of
quality control measures in the original studies. These
measures included re-genotyping of random samples by
separate methods and Hardy–Weinberg testing. Detailed
information on primers, probes, and other conditions for
genotyping are available upon request.
Phenotypes/outcomes
Phenotypes/outcomes of main interest were (i) EH classified
according to the World Health Organization (WHO) criteria
(SBP C 140 and/or DBP C 90 and/or use of anti-hyperten-
sive drugs, in the absence of secondary forms of hyperten-
sion), (ii) overweight plus obesity defined as body mass index
(BMI) C25 kg/m2 and (iii) continuous traits, including both
SBP and DBP and BMI. Secondary outcomes were (i) EH
defined as SBP C 160 and/or DBP C 100 and/or use of anti-
hypertensive drugs and (ii) obesity only, defined as a
BMI C 30 kg/m2. Throughout the analyses, normotensive
controls subjects were defined as those participants with a
SBP \ 140 and DBP \ 90 and no history of use of anti-
hypertensive drugs, whereas lean controls subjects were
defined as those participants with a BMI \ 25 kg/m2. In order
to avoid shrinkage in estimated effects for continuous vari-
ables, blood pressure levels in participants taking antihyper-
tensive drugs were adjusted by adding 15 and 10 mm Hg for
SBP and DBP, respectively, as described previously [12].
Statistical analysis
Univariate meta-analysis
We estimated summary effects of individual GNB3 poly-
morphisms on cardiovascular phenotypes using the Der-
Simonian–Laird method, which is a method-of-moments-
based random-effects model [13]. We fit both additive and
recessive models for markers with a minor allele frequency
(MAF) below 30 %, and only an additive model for
markers with a MAF C 30 %. Whenever two models of
analysis were fit, results were correct by the Bonferroni
method. This approach maximizes statistical power for
variants that are less common in the populations, while
reducing the likelihood of a type-I error (i.e. false-positive
associations) in the analyses involving common markers
[14, 15].
The effect of individual variants on binary outcomes
was captured as the natural logarithm of the odds ratio
(OR) by means of multiple logistic regression models
adjusted for age, gender and BMI when appropriate. For
continuous traits, we fit a multiple linear regression model
also adjusted for covariates. The effect size for continuous
traits has the same units as the original variables and is
captured as the expected linear increment (D) in the trait
per additional copy of the risk-allele.
Haplotype estimation
For n biallelic markers, there are 2n possible haplotypes,
yielding 2n - 1 estimated haplotypic effects, which are
obtained by comparing individual haplotypes with a ref-
erence haplotype, that is, the ‘‘each haplotype versus the
reference haplotype’’ approach. For the ith study, a gen-
eralized linear model was employed to infer haplotypes,
whereas simultaneously estimating haplotype frequencies
and a vector haplotype effects [16]. The flexible general-
ized linear model applied here accounts for the uncertainty
in haplotype assignment and permits the adjustment for
covariates. Parameter estimates were obtained by the use of
the expectation maximization (EM) algorithm, in which the
extra uncertainty due to the unknown phase is taken into
account, resulting in wider standard errors [16]. The vari-
ance–covariance matrix of regression parameters for each
individual study was obtained as discussed previously [17].
For the present analyses, the haplotype containing only
non-risk alleles was defined as the reference haplotype [6].
The regression schemes were consistently coined across
studies to take into account a potential heterogeneity in the
haplotypic frequencies. Inferences on the fit of alternative
models (i.e. presence of statistically significant haplotypic
effects) were carried out by using likelihood-ratio tests in a
two-stage procedure as described elsewhere [4].
Multivariate meta-analysis
In our case, multivariate meta-analysis explicitly models
the relationship between correlated haplotypic effects
within studies, ultimately producing more appropriate
confidence intervals and P values [6]. Briefly, the method
Table 1 Characteristics of the genetic markers investigated
SNP rs Location Functional
effect?
References
G-350A rs5441 Promoter No/unknown
C825T rs5443 Exon 10 Yes [1]
C1429T rs5446 30-Untranslated
region
No/unknown
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uses haplotypic effects (i.e. log of OR or D) obtained from
the comparison of each of the 2n - 1 haplotypes against a
reference haplotype and then models simultaneously the
2n - 1 haplotypic effects in a standard multivariate meta-
analysis, taking into account the within-studies correlations
that arise since the same reference group is included in
each comparison. To fit the multivariate model, one
requires not only the within-study variance for each effect,
but also an estimate of the within-study covariance among
haplotypic effects [18].
We fit a random-effects multivariate meta-analysis, in
which the jth possible haplotypic effect
(j = 1,…,J = 2n - 1) estimated in the study i (Yij) for
i = 1,…,k has a within-study sample variance assumed to
be known of r2ij. Haplotypic effects are considered to be a
realization of the following model:
Yi1
..
.
Yij
0
BB@
1
CCAMVN b ¼
bi1
..
.
biJ
0
BB@
1
CCA;
0
BB@
X ¼
r2i1    ri1riJqws
..
. . .
. ..
.
r2i1riJqws . . . r
2
iJ
0
BB@
1
CCA
1
CCA;
ð1Þ
where b is the J 9 1 vector of population specific
haplotypic effects, X is the J 9 J within-study variance–
covariance matrix, qws is the within-study correlation
between effects and MVN stands for the multivariate
Normal distribution. Population specific effects (bij) with
correspondent between-study variance (s2j ) are further
assumed to be distributed as:
bi1
..
.
biJ
0
BB@
1
CCAMVN l ¼
l1
..
.
lJ
0
BB@
1
CCA;
0
BB@
X
¼
s21 . . . s1sJqbs
..
. . .
. ..
.
s1sJqbs    s2J
0
BB@
1
CCA
1
CCA
ð2Þ
where l is the J 9 1 vector of average population specific
haplotypic effects,
P
is the J 9 J between-study variance–
covariance matrix and qbs is the between-study correlation
between effects. Both l and
P
were estimated according the
methodology described in detail elsewhere [19]. Hypothesis
testing was carried out by multivariate Wald tests.
Statistical heterogeneity among haplotypic effects was
assessed by the Cochran’s Q-statistic [19, 20], and the I2
metric, which is the proportion of total variance of the
pooled effect measure because of genuine statistical het-
erogeneity (i.e. due to between-study variance, and not to
chance) [21]. Given the relatively large number of phe-
notypes and sub-groups studied (i.e. multiple testing), we
considered a P \ 0.01 as a significant evidence for
departures from HWE proportions. Similarly, for both
haplotype- and meta-analysis-based inferences, a P \ 0.01
was judged significant. For the Q-statistic, a test with rel-
atively low power in most scenarios [20], a significance
level of P \ 0.1 was chosen. Statistical analyses were
carried out in Stata 11.1 package (Stata Corporation, Col-
lege Station, TX, USA) and R (version 2.81).
Sensitivity analyses
Besides the main analyses, we also carried out multivariate
meta-analyses of haplotypic effects (i) testing for non-
additive effects (i.e. both dominant and recessive models of
action), (ii) excluding studies with markers not in Hardy–
Weinberg Equilibrium, (iii) testing for gender-specific
effects and (iv) considering only subjects without antihy-
pertensive treatment. In addition, two other outcomes were
investigated: a more severe stage of hypertension (defined
as a SBP C 160 and/or DBP C 100 and/or use of anti-
hypertensive) and obesity classified according to a
BMI C 30 kg/m2. We further performed a fixed-effects
pooled analyses encompassing each set of available stud-
ies, but added an additional term on the model referring the
to study specific effects. We performed analyses in non-
diabetic subjects only, Japanese participants only and
repeated the main analysis adjusting for all available study-
specific covariates (e.g. total cholesterol, glucose, physical
activity) when available. Finally, we applied an univariate
random-effects meta-analysis for each outcome under an
assumption of varying effect sizes between studies [22].
Results
Characteristics of the participant studies
A total of six studies [23–29] were found. Of these, one
[29] did not met our eligibility criteria (i.e. twin study). The
selected characteristics of the six participating studies are
shown in Table 2. All studies were published between
2005 and 2011.
Single-marker-based meta-analysis
The G-350A promoter variant
Four investigations encompassing 7,292 participants (2,738
hypertensives and 4,554 normotensives; 3,550 overweight
and 3,742 lean) were available for the association of the
G-350A promoter variant with both blood pressure- and
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adiposity-related phenotypes [23, 26, 28, 30]. All controls
groups were in Hardy–Weinberg equilibrium (Supple-
mentary Tables S1–S2). Overall, there was moderate to
high degree of heterogeneity among study results, with the
odds of essential hypertension, odds of overweight and
DBP yielding nominally statistically significant evidence
for statistical heterogeneity. Under an additive model, no
evidence for an effect of the -350A allele on any of the
investigated phenotypes was observed (Table 3).
The C825T polymorphism in exon 10
All selected studies contributed with genotypic information
in relation to the C825T polymorphism, yielding a total of
up 15,960 participants with available data: 8,586 hyper-
tensives and 7,372 normotensives; 6,133 overweight and
9,827 lean. The study by Suwazono et al. [30]. showed
evidence for a departure from the Hardy–Weinberg pro-
portions (exact P value = 0.003 and 0.008 for controls in
EH and overweight, respectively (Supplementary Tables
S3–S4). Statistical heterogeneity was observed for DBP,
BMI and odds of overweight. Random-effects summary
estimates computed under an additive model suggested that
the 825T allele has no influence on any of the investigated
traits (Table 3).
The C1429T variant at the 30-untranslated region
For the C1429T variant, data from up to 12259 participants
from four studies (6,642 hypertensives and 5,633 normo-
tensives; 3,581 overweight and 8,678 lean) were available
[23, 27, 30, 31]. For the odds of hypertension, controls
subjects from the study by Suwazono et al. [30]. and
Yamada et al. [31]. did not fit Hardy–Weinberg expecta-
tions (exact P values ranging from 0.005 to 0.001) (Sup-
plementary Tables S5–S6). Confidence intervals for
random-effects-based summary estimates overlap with null
effects for all of the investigated phenotypes, indicating no
prominent role of the 1429T allele in these traits (Table 3).
Haplotype-based meta-analysis
G-350A–C825T haplotypes
Four studies had participants genotyped for both G-350A
and C825T variants, enabling haplotypic analyses that
encompassed 7,292 participants (2,738 hypertensives and
Table 3 Summary results for the univariate meta-analyses
Phenotype/outcome No. of
participants
No. of
studies
Effect size Summary effect (95 % CI) P value Heterogeneity
I2 (95 % CI) P(Q) s2
G-350A (rs5441)
Essential hypertension 7,313 4 OR 1.072 (0.807, 1.445) 0.571 55 % (0–85 %) 0.085 0.042
SBP (mmHg) 7,310 4 D -0.592 (-1.568, 0.385) 0.235 0 % (0–85 %) 0.454 0
DBP (mmHg) 7,310 4 D -0.055 (-1.338, 1.228) 0.933 44 % (0–81 %) 0.149 0.741
Overweight 7,313 4 OR 1.037 (0.802, 1.306) 0.880 51 % (0–84 %) 0.108 0.030
BMI (kg/m2) 7,313 4 D 0.011 (-0.170, 0.193) 0.650 0 % (0–85 %) 0.440 0
C825T (rs5443)
Essential hypertension 15,959 6 OR 0.977 (0.927, 1.029) 0.376 0 % (0–75 %) 0.423 0
SBP (mmHg) 15,959 6 D 0.095 (-0.358, 0.547) 0.682 0 % (0–75 %) 0.644 0
DBP (mmHg) 15,959 6 D -0.186 (-0.688, 0.316) 0.468 63 % (10–85 %) 0.019 0.219
Overweight 15,959 6 OR 0.975 (0.904, 1.052) 0.521 48 % (0–79 %) 0.087 0.004
BMI (kg/m2) 15,959 6 D -0.045 (-0.191, 0.100) 0.541 65 % (17–86 %) 0.013 0.019
C1429T (rs5446)
Essential hypertension 12,259 4 OR 1.002 (0.930, 1.080) 0.958 0 % (0–85 %) 0.875 0
SBP (mmHg) 12,257 4 D 0.216 (-0.415, 0.847) 0.502 0 % (0–85 %) 0.625 0
DBP (mmHg) 12,257 4 D 0.150 (-0.254, 0.554) 0.468 0 % (0–85 %) 0.826 0
Overweight 12,259 4 OR 0.982 (0.914, 1.055) 0.623 0 % (0–85 %) 0.688 0
BMI (kg/m2) 12,259 4 D -0.011 (-0.114, 0.092) 0.836 0 % (0–85 %) 0.583 0
All results refer to the (log-)additive model of analysis and are adjusted for age, gender and BMI, or for age and gender only when appropriate.
Analyses were also performed under a recessive model of analysis, yielding qualitatively analogous results (data not shown)
DBP diastolic blood pressure, SBP systolic blood pressure, OR odds ratio, D expected linear increment in the trait per additional copy of the risk-
allele, s2 estimated between-study variance, P(Q) P value for the Cochran’s Q test
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4,554 normotensives; 3,550 overweight and 3,742 lean)
[23, 26, 28, 30]. While a distinct pattern of LD among
populations of different ancestries is observed, we found
evidence for a significant LD and high to moderate D0
scores between the G-350A variant and the C825T poly-
morphism (P \ 0.01 for all studies, Supplementary Table
S7). Among Japanese, the two common haplotypes GC and
GT captured [98 % of the chromosomes, but only
60–70 % in other ancestries.
Under a multivariate random-effects meta-analysis with
additive effects, none of the three haplotypes containing
risk alleles (i.e. GT, CA, and AT) showed significant evi-
dence of association with the investigated traits compared
to the reference GC haplotype. Overall, evidence for het-
erogeneity was only observed for the odds of hypertension.
For this trait, heterogeneity was observed in both magni-
tude and direction of the effects (Table 4).
C825T–C1429T haplotypes
Data from 12,259 participants from four studies [23, 27,
30, 31] were available to test the association of the C825T–
C1249T haplotypes with cardiovascular phenotypes (6,644
hypertensives and 5,615 normotensives; 3,581 overweight
and 8,678 lean). All participants were of Asian descent.
Both D0 and R2 measures suggested significant LD, which
was observed to be consistent among studies (Supple-
mentary Table S9).
When studies were combined through a random-effects
multivariate meta-analysis, none of the inferred haplotypes
displayed a significant effect on the investigated traits
compared to the reference CC haplotype (Table 5).
G-350A–C1429T haplotypes
Both G-350A and C1429T variants were genotyped in two
studies [23, 30], yielding an analysis that incorporated data
from 3649 subjects of Asian ancestry (813 hypertensives
and 2,836 normotensives; 1,026 overweight and 2,623
lean). Given that the -350A and 1429T alleles are typi-
cally uncommon in Asian populations, a single common
haplotype (i.e. the basal GC haplotype) captured C75 % of
the chromosomes and there was evidence for linkage dis-
equilibrium (Supplementary Table S10). Under a random-
effects meta-analysis, none of the inferred G-350A–
C1429T haplotypes showed significant effects on the
studied phenotypes compared to the GC reference haplo-
type (Table 6).
G-350A–C825T–C1429T haplotypes
Inferences on the effect of the G-350A–C825T–C1429T
haplotypes on blood pressure and adiposity-related traits
was possible in the same set of subjects from the previous
analysis (3,649 participants of Asian descent) [23, 30].
Among the eight possible haplotypes, three were most
common, capturing [97 % of the chromosomes. Due to
convergence problems originated from haplotypes with
very low frequency, we pooled uncommon haplotypes into
a single category (Supplementary Table S11). Under a
random-effects multivariate meta-analysis, no significant
association was detected between the two most common
haplotypes (i.e. GTC and GTT) and the pooled category
(all haplotypes with a frequency below 3 %) with any of
the studied phenotypes (Table 7).
Sensitivity analyses
No significant effects were observed in any of these sen-
sitivity analyses (data not shown).
Discussion
Main findings
The present study is a comprehensive, carefully conducted
international collaborative meta-analysis of individual
patient data that reviewed the role of GNB3 haplotypes in
five traits of cardiovascular importance. By using partici-
pant-level data from 16068 subjects, our results do not
support the hypothesis of significant effects of GNB3
polymorphism/haplotypes neither on the risk of essential
hypertension and overweight nor on continuous traits such
as SBP, DBP and BMI.
Agreements and disagreements with other studies
or systematic reviews
Considering the evidence as a whole, our findings are in
line with recent meta-analyses on the association of indi-
vidual GNB3 markers and hypertension that used summary
data [32, 33]. Recent large-scale association studies also
suggest no evidence for an association between GNB3
polymorphisms either with systolic and diastolic blood
pressures as continuous variables or essential hypertension
as a dichotomous phenotype [34].
Dong et al. [29] were the first to present evidence for
GNB3 haplotypic effects on cardiovascular-related pheno-
types in a sample of female dizygotic twins. According to
the authors, there was evidence for a complex interaction
among GNB3 haplotypes versus obesity versus hyperten-
sion. Among the six studies included in the present sys-
tematic review, only two [23, 28] explicitly investigated
and claimed a role for GNB3 haplotypes in cardiovascular-
related phenotypes. For example, Li et al. [23] revealed the
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Table 4 Multivariate meta-analysis of haplotypic effects (G-350A/C825T) on cardiovascular phenotypes
Trait/study Haplotype comparison
GT versus GC P value AC versus GC P value AT versus GC P value
EH OR (95 % CI) OR (95 % CI) OR (95 % CI)
Kimura et al. [28] 0.586 (0.358, 0.958) 0.033 0.591 (0.336, 1.040) 0.068 0.865 (0.451, 1.659) 0.661
Li et al. [23] 0.999 (0.828, 1.206) 0.994 2.165 (1.060, 4.423) 0.034 NE NE
Renner et al. [26] 0.856 (0.745, 0.983) 0.027 0.883 (0.777, 1.003) 0.055 0.849 (0.603, 1.195) 0.348
Suwazono et al. [24] 1.085 (0.907, 1.298) 0.370 0.620 (0.092, 4.173) 0.622 2.246 (0.298, 26.93) 0.432
Summary OR 0.924 (0.773, 1.104) 0.385 1.103 (0.651, 1.867) 0.716 0.938 (0.509, 1.727) 0.838
Cochran0s Q test 8.18 (3) 0.042 8.12 (3) 0.044 0.87 (2) 0.648
I2 (95 % CI) 67 % (0–92 %) 66 % (0–92 %) 2 % (0–84 %)
SBP D (95 % CI) d (95 % CI) D (95 % CI)
Kimura et al. [28] -2.208 (-6.734, 2.318) 0.339 -0.482 (-5.95, 4.986) 0.862 -1.361 (-7.39, 4.67) 0.658
Li et al. [23] 0.854 (-2.020, 3.727) 0.560 4.652 (-5.025, 14.33) 0.346 14.96 (-16.68, 46.60) 0.354
Renner et al. [26] -1.194 (-2.62, 0.231) 0.100 -1.491 (-2.811, -0.172) 0.026 0.130 (-3.438, 3.697) 0.943
Suwazono et al. [24] 0.180 (-0.618, 0.977) 0.658 -2.059 (-7.19, 3.075) 0.431 3.514 (-6.330, 13.36) 0.484
Summary D -0.284 (-1.506, 0.936) 0.648 -0.638 (-3.330, 2.054) 0.642 0.609 (-3.068, 4.287) 0.745
Cochran0s Q test 3.98 (3) 0.264 1.69 (3) 0.639 1.53 (3) 0.675
I2 (95 % CI) 37 % (0–84 %) 9 % (0–73 %) 3 % (0–69 %)
DBP D (95 % CI) D (95 % CI) D (95 % CI)
Kimura et al. [28] -1.247 (-3.878, 1.383) 0.352 -2.328 (-5.447, 0.792) 0.143 -1.996 (-5.596, 1.605) 0.277
Li et al. [23] 0.238 (-1.269, 1.744) 0.757 4.006 (-1.327, 9.338) 0.141 2.802 (-14.23, 19.83) 0.747
Renner et al. [26] -1.063 (-1.787, -0.338) 0.004 -0.041 (-0.712, 0.630) 0.905 -1.558 (-3.350, 0.233) 0.088
Suwazono et al. [24] -0.110 (-0.678, 0.458) 0.705 -0.580 (-4.078, 2.918) 0.745 -1.348 (-8.50, 5.807) 0.711
Summary D -0.413 (-1.066, 0.240) 0.216 -0.202 (-1.531, 1.126) 0.765 -1.388 (-3.408, 0.632) 0.178
Cochran0s Q test 5.28 (3) 0.153 4.34 (3) 0.227 0.31 (3) 0.958
I2 (95 % CI) 42 % (0–83 %) 3 % (0–60 %) 1 % (0–51 %)
Overweight OR (95 % CI) OR (95 % CI) OR (95 % CI)
Kimura et al. [28] 0.998 (0.654, 1.524) 0.993 0.910 (0.549, 1.508) 0.714 1.171 (0.659, 2.0.81) 0.591
Li et al. [23] 0.956 (0.797, 1.147) 0.628 1.807 (0.923, 3.536) 0.084 2.291 (0.237, 22.10) 0.473
Renner et al. [26] 1.006 (0.869, 1.164) 0.936 0.932 (0.815, 1.066) 0.301 0.992 (0.688, 1.431) 0.966
Suwazono et al. [24] 0.973 (0.843, 1.124) 0.710 0.406 (0.129, 1.281) 0.124 2.026 (0.476, 8.623) 0.339
Summary OR 0.983 (0.900, 1.072) 0.694 0.979 (0.633, 1.51) 0.925 1.112 (0.732, 1.705) 0.694
Cochran0s Q test 0.21 (3) 0.976 5.72 (3) 0.126 1.43 (3) 0.699
I2 (95 % CI) 1 % (0–60 %) 23 % (0–95 %) 6 % (0–83 %)
BMI D (95 % CI) D (95 % CI) D (95 % CI)
Kimura et al. [28] 0.464 (-0.335, 1.262) 0.255 0.764 (-0.184, 1.711) 0.114 0.532 (-0.567, 1.630) 0.342
Li et al. [23] -0.127 (-0.471, 0.217) 0.468 0.319 (-0.849, 1.488) 0.592 1.444 (-1.906, 4.794) 0.398
Renner et al. [26] 0.044 (-0.227, 0.315) 0.749 -0.071 (-0.322, 0.180) 0.579 0.486 (-0.220, 1.192) 0.177
Suwazono et al. [24] -0.035 (-0.205, 0.135) 0.688 -0.570 (-1.559, 0.419) 0.250 1.204 (-0.882, 3.290) 0.259
Summary D -0.017 (-0.149, 0.115) 0.799 -0.059 (-0.456, 0.338) 0.771 0.503 (-0.053, 1.060) 0.076
Cochran0s Q test 2.02 (3) 0.568 4.29 (3) 0.232 0.67 (3) 0.879
I2 (95 % CI) 0 % (0–65 %) 3 % (0–93 %) 0 % (0–71 %)
D expected linear increment in the trait per additional copy of the haplotype. D is interpreted in the same unit as the original variable. All results refer to the
additive model of analysis and are adjusted for age, gender and BMI, or for age and gender only when appropriate. Analyses were also performed under
both dominant and recessive models of analysis, yielding qualitatively analogous results (data not shown). Results for the Cochran0s Q test are given as Chi
squared values (degrees-of-freedom)
EH essential hypertension, NE not estimated, OR odds ratio
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Table 5 Multivariate meta-analysis of haplotypic effects (C825T/C1429T) on cardiovascular phenotypes
Trait/study Haplotype comparison
CT versus CC P value TC versus CC P value TT versus CC P value
EH OR (95 % CI) OR (95 % CI) OR (95 % CI)
Daimon et al. [27] NE NE 0.944 (0.828, 1.075) 0.384 0.964 (0.826, 1.126) 0.643
Li et al. [23] 0.661 (0.194, 2.259) 0.509 0.912 (0.733, 1.133) 0.405 1.061 (0.835, 1.349) 0.626
Suwazono et al. [24] 1.332 (0.447, 3.968) 0.267 1.120 (0.917, 1.368) 0.559 1.075 (0.843, 1.370) 0.293
Yamada et al. [25] 0.267 (0.121, 0.589) 0.001 0.965 (0.875, 1.064) 0.474 1.011 (0.902, 1.134) 0.846
Summary OR 0.537 (0.209, 1.379) 0.196 0.978 (0.901, 1.06) 0.606 1.015 (0.926, 1.112) 0.748
Cochran0s Q test 5.71 (2) 0.058 2.47 (3) 0.481 0.76 (3) 0.858
I2 (95 % CI) 60 % (0–90 %) 11 % (0–76 %) 3 % (0–69 %)
SBP D (95 % CI) D (95 % CI) D (95 % CI)
Daimon et al. [27] -8.119 (-31.69, 15.45) 0.500 -0.315 (-1.340, 0.710) 0.547 -0.035 (-1.253, 1.182) 0.954
Li et al. [23] -7.732 (-26.09, 10.63) 0.409 0.959 (-2.378, 4.296) 0.573 0.217 (-3.481, 3.915) 0.908
Suwazono et al. [24] 0.999 (-3.75, 5.749) 0.680 0.016 (-0.888, 0.921) 0.971 0.700 (-0.388, 1.788) 0.207
Yamada et al. [25] -10.280 (-19.95, -0.611) 0.037 0.720 (-0.408, 1.848) 0.210 0.240 (-1.070, 1.550) 0.719
Summary D -4.491 (-12.59, 3.616) 0.278 0.163 (-0.485, 0.812) 0.621 0.295 (-0.425, 1.015) 0.422
Cochran0s Q test 4.96 (3) 2.07 (3) 0.558 0.81 (3) 0.847
I2 (95 % CI) 46 % (0–83 %) 13 % (0–76 %) 6 % (0–67 %)
DBP D (95 % CI) D (95 % CI) D (95 % CI)
Daimon et al. [27] -11.922 (-27.04, 3.197) 0.122 -0.335 (-0.989, 0.319) 0.315 0.272 (-0.505, 1.048) 0.492
Li et al. [23] -7.180 (-16.80, 2.444) 0.143 -0.375 (-2.119, 1.368) 0.673 0.476 (-1.456, 2.409) 0.629
Suwazono et al. [24] 1.988 (-1.345, 5.321) 0.242 0.018 (-0.626, 0.661) 0.957 -0.213 (-0.988, 0.562) 0.589
Yamada et al. [25] -5.751 (-11.44, -0.060) 0.047 0.383 (-0.271, 1.038) 0.251 0.442 (-0.319, 1.202) 0.255
Summary D -4.192 (-10.7, 2.325) 0.207 -0.003 (-0.386, 0.379) 0.986 0.203 (-0.296, 0.702) 0.425
Cochran0s Q test 9.35 (3) 0.025 2.50 (3) 0.475 1.59 (3) 0.662
I2 (95 % CI) 53 % (0–87 %) 43 % (0–83 %) 1 % (0–63 %)
Overweight OR (95 % CI) OR (95 % CI) OR (95 % CI)
Daimon et al. [27] NE NE 0.816 (0.717, 0.929) 0.002 0.909 (0.781, 1.059) 0.219
Li et al. [23] 1.592 (0.457, 5.542) 0.468 0.884 (0.716, 1.091) 0.251 1.044 (0.826, 1.318) 0.720
Suwazono et al. [24] 0.881 (0.359, 2.162) 0.782 1.014 (0.862, 1.192) 0.871 0.947 (0.777, 1.154) 0.590
Yamada et al. [25] 0.796 (0.332, 1.906) 0.608 1.071 (0.975, 1.176) 0.150 1.008 (0.904, 1.125) 0.883
Summary OR 1.074 (0.499, 2.315) 0.854 0.945 (0.824, 1.082) 0.416 0.968 (0.889, 1.055) 0.467
Cochran0s Q test 0.84 (2) 0.656 12.16 (3) 0.007 1.58 (3) 0.664
I2 (95 % CI) 23 % (0–85 %) 73 % (0–92 %) 13 % (0–69 %)
BMI D (95 % CI) D (95 % CI) D (95 % CI)
Daimon et al. [27] -1.808 (-6.041, 2.425) 0.402 -0.342 (-0.530, -0.153) 0.0004 -0.218 (-0.443, 0.007) 0.057
Li et al. [23] 0.893 (-1.393, 3.178) 0.443 -0.342 (-0.530, 0.153) 0.201 0.090 (-0.353, 0.532) 0.691
Suwazono et al. [24] 0.045 (-0.928, 1.019) 0.927 -0.001 (-0.193, 0.191) 0.992 -0.041 (-0.272, 0.190) 0.727
Yamada et al. [25] -0.268 (-1.503, 0.967) 0.670 0.074 (-0.063, 0.210) 0.289 0.050 (-0.108, 0.208) 0.537
Summary D -0.001 (-0.952, 0.950) 0.998 -0.111 (-0.323, 0.101) 0.304 -0.060 (-2.14, 0.938) 0.442
Cochran0s Q test 1.47 (3) 0.689 13.56 (3) 0.004 3.96 (3) 0.266
I2 (95 % CI) 1 % (0–74 %) 76 % (0–93 %) 42 % (0–82 %)
D is interpreted in the same unit as the original variable. All results refer to the additive model of analysis and are adjusted for age, gender and
BMI, or for age and gender only when appropriate. Analyses were also performed under both dominant and recessive models of analysis,
yielding qualitatively analogous results (data not shown). Results for the Cochran0s Q test are given as Chi squared values (degrees-of-freedom)
EH essential hypertension, NE not estimated, OR odds ratio, D expected linear increment in the trait per additional copy of the haplotype
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potential of haplotypic effects when assessing the influence
of GNB3 polymorphisms on the risk of hypertension in
Chinese. Recently, by using a family-based design and
dimensionality reduction techniques, Kimura et al. [28]
were able to observe that both G-350A and C825T variants
might interact to determine DBP levels in an African-
derived Brazilian population. It is important to note that, in
all of the three studies mentioned above, significant results
were obtained after multiple testing, and were only mar-
ginally significant with P values ranging from 0.01 to 0.04.
Study strengths and limitations
A relatively large number of participants with individual
data might be considered a strong point in our work.
Indeed, a key aspect of our investigation is that our results
Table 6 Multivariate meta-analysis of haplotypic effects (G-350A/C1429T) on cardiovascular phenotypes
Trait/study Haplotype comparison
GT versus GC P value AC versus GC P value AT versus GC P value
EH OR (95 % CI) OR (95 % CI) OR (95 % CI)
Li et al. [23] 1.113 (0.885, 1.400) 0.358 2.302 (1.144, 4.633) 0.019 1.316 (0.102, 16.96) 0.833
Suwazono et al. [24] 1.042 (0.833, 1.304) 0.370 0.945 (0.341, 2.616) 0.622 1.109 (0.020, 62.95) 0.432
Summary OR 1.076 (0.910, 1.272) 0.390 1.573 (0.634, 3.900) 0.328 1.22 (0.122, 12.13) 0.865
Cochran0s Q test 0.16 (1) 0.686 2.00 (1) 0.158 0.005 (1) 0.944
I2 (95 % CI) 9 % (0–85 %) 53 % (0–93 %) 0 % (0–80 %)
SBP D (95 % CI) D (95 % CI) D (95 % CI)
Li et al. [23] -0.407 (-3.905, 3.090) 0.819 4.782 (-4.585, 14.149) 0.317 13.109 (-27.84, 54.05) 0.530
Suwazono et al. [24] 0.752 (-0.253, 0.756) 0.140 0.065 (-4.049, 4.179) 0.975 -6.184 (-21.69, 9.319) 0.434
Summary D 0.395 (-1429, 2.219) 0.671 1.724 (-4.294, 7.743) 0.574 0.128 (-25.15, 25.41) 0.992
Cochran0s Q test 0.39 (1) 0.532 0.82 (1) 0.366 0.75 (1) 0.388
I2 (95 % CI) 18 % (0–87 %) 31 % (0–90 %) 29 % (0–89 %)
DBP D (95 % CI) D (95 % CI) D (95 % CI)
Li et al. [23] 0.500 (-1.356, 2.356) 0.597 4.073 (-1.211, 9.356) 0.130 1.707 (-22.56, 25.979) 0.890
Suwazono et al. [24] -0.113 (-0.829, 0.603) 0.756 -0.883 (-3.825, 2.058) 0.556 0.546 (-9.973, 11.066) 0.919
Summary D 0.117 (-0.931, 1.166) 0.826 1.180 (-3.869, 6.230) 0.647 1.140 (-11.06, 13.35) 0.962
Cochran0s Q test 0.37 (1) 0.546 2.58 (1) 0.108 0.01 (1) 0.931
I2 (95 % CI) 20 % (0–87 %) 63 % (0–94 %) 0 % (0–81 %)
Overweight OR (95 % CI) OR (95 % CI) OR (95 % CI)
Li et al. [23] 1.116 (0.895, 1.392) 0.328 1.828 (0.984, 3.395) 0.056 NE NE
Suwazono et al. [24] 0.923 (0.768, 1.110) 0.396 0.504 (0.189, 1.341) 0.169 NE NE
Summary OR 1.012 (0.811, 1.265) 0.911 1.002 (0.275, 3.648) 0.997 NE NE
Cochran0s Q test 1.67 (1) 0.196 4.75 (1) 0.029 NE
I2 (95 % CI) 58 % (0–93 %) 80 % (0–97 %)
BMI D (95 % CI) D (95 % CI) D (95 % CI)
Li et al. [23] 0.203 (-0.213, 0.620) 0.339 0.428 (-0.686, 1.541) 0.451 2.129 (-1.865, 6.123) 0.296
Suwazono et al. [24] -0.064 (-0.277, 0.148) 0.553 -0.592 (-1.446, 0.262) 0.174 5.323 (1.206, 9.441) 0.012
Summary D 0.050 (-0.275, 0.375) 0.762 -0.121 (-1.241, 0.999) 0.832 3.742 (-0.217, 7.701) 0.064
Cochran0s Q test 1.26 (1) 0.262 2.03 (1) 0.155 1.19 (1) 0.275
I2 (95 % CI) 49 % (0–92 %) 61 % (0–94 %) 48 % (0–92 %)
D is interpreted in the same unit as the original variable. All results refer to the additive model of analysis and are adjusted for age, gender and
BMI, or for age and gender only when appropriate. Analyses were also performed under both dominant and recessive models of analysis,
yielding qualitatively analogous results (data not shown). Results for the Cochran’s Q test are given as Chi squared values (degrees-of-freedom)
EH essential hypertension, NE not estimated, OR odds ratio, D expected linear increment in the trait per additional copy of the haplotype
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are less prone to reporting bias, since all data from each
individual study were used in our analyses. All results were
summarized after adjustment for the same covariates and
are presented in a uniform manner. Criticism might be
directed at the fact that we meta-analyzed data from sam-
ples with substantial differences in genetic background
(three Japanese, one Chinese, one European and one Bra-
zilian with African ancestry). However, we consider the
use of multiethnic samples a further strength in our work.
In fact, it is well-known that single populations can only
capture a limited proportion of the total human genetic
variation. By analyzing data from diverse populations, we
were unable to detect strong support for the association of
GNB3 haplotypes either at an individual study or at a meta-
analysis level. Although these findings do not rule out
small, population-specific effects, we might consider less
likely large effects of GNB3 haplotypes on cardiovascular
phenotypes in the studied populations.
Table 7 Multivariate meta-analysis of haplotypic effects (G-350A/C825T/C1429T) on cardiovascular phenotypes
Trait/study Haplotype comparison
GTC versus GCC P value GTT versus GCC P value Pooled versus GCC P value
EH OR (95 % CI) OR (95 % CI) OR (95 % CI)
Li et al. [23] 0.942 (0.756, 1.173) 0.592 1.086 (0.851, 1.386) 0.506 1.735 (1.002, 3.006) 0.049
Suwazono et al. [24] 1.113 (0.910, 1.360) 0.296 1.073 (0.841, 1.370) 0.569 1.139 (0.567, 2.288) 0.715
Summary OR 1.028 (0.844, 1.252) 0.783 1.080 (0.908, 1.284) 0.383 1.433 (0.827, 2.481) 0.200
Cochran0s Q test 1.21 (1) 0.271 0.005 (1) 0.946 0.87 (1) 0.352
I2 (95 % CI) 43 % (0–91 %) 0 % (0–80 %) 35 % (0–90 %)
SBP D (95 % CI) D (95 % CI) D (95 % CI)
Li et al. [23] 0.679 (-2.791, 4.149) 0.701 0.493 (-3.382, 4.367) 0.803 4.668 (-3.773, 13.11) 0.278
Suwazono et al. [24] -0.031 (-0.955, 0.893) 0.947 0.665 (-0.447, 0.177) 0.241 0.413 (-2.682, 3.508) 0.793
Summary D 0.247 (-1.199, 1.249) 0.968 0.646 (-0.445, 1.737) 0.246 0.924 (-4.411, 6.270) 0.711
Cochran0s Q test 0.15 (1) 0.698 0.01 (1) 0.933 0.86 (1) 0.354
I2 (95 % CI) 0 % (0–98 %) 0 % (0–87 %) 0 % (0–99 %)
DBP D (95 % CI) D (95 % CI) D (95 % CI)
Li et al. [23] -0.482 (-2.334, 1.369) 0.609 0.722 (-1.347, 2.792) 0.493 2.764 (-1.756, 7.283) 0.230
Suwazono et al. [24] -0.006 (-0.668, 0.655) 0.984 -0.242 (-1.038, 0.555) 0.551 0.459 (-1.736, 2.654) 0.681
Summary D -0.158 (-1.097, 0.7812) 0.742 0.079 (-1.191, 1.349) 0.902 1.285 (-1.689, 4.258) 0.397
Cochran0s Q test 0.23 (1) 0.635 0.73 (1) 0.394 0.81 (1) 0.369
I2 (95 % CI) 11 % (0–85 %) 29 % (0–89 %) 31 % (0–90 %)
Overweight OR (95 % CI) OR (95 % CI) OR (95 % CI)
Li et al. [23] 0.905 (0.732, 1.120) 0.359 1.058 (0.835, 1.341) 0.641 1.852 (1.072, 3.197) 0.027
Suwazono et al. [24] 1.005 (0.855, 1.183) 0.947 0.929 (0.761, 1.134) 0.468 0.785 (0.435, 1.414) 0.419
Summary OR 0.956 (0.812, 1.126) 0.597 0.989 (0.814, 1.202) 0.916 1.211 (0.506, 2.90) 0.668
Cochran0s Q test 0.59 (1) 0.442 0.68 (1) 0.409 4.39 (1) 0.036
I2 (95 % CI) 33 % (0–89 %) 37 % (0–90 %) 79 % (0–97 %)
BMI D (95 % CI) D (95 % CI) D (95 % CI)
Li et al. [23] -0.255 (-0.656, 0.147) 0.214 0.091 (-0.357, 0.540) 0.689 0.567 (-0.413, 1.547) 0.257
Suwazono et al. [24] -0.005 (-0.198, 0.187) 0.956 -0.059 (-0.292, 0.174) 0.621 -0.032 (-0.670, 0.606) 0.920
Summary D -0.107 (-0.408, 0.194) 0.487 0.004 (-0.268, 0.277) 0.974 0.233 (-0.529, 0.995) 0.549
Cochran0s Q test 1.20 (1) 0.273 0.34 (1) 0.560 1.01 (1) 0.315
I2 (95 % CI) 46 % (0–92 %) 20 % (0–87 %) 42 % (0–91 %)
D is interpreted in the same unit as the original variable. All results refer to the additive model of analysis and are adjusted for age, gender and
BMI, or for age and gender only when appropriate. Analyses were also performed under both dominant and recessive models of analysis,
yielding qualitatively analogous results (data not shown). Results for the Cochran’s Q test are given as Chi squared values (degrees-of-freedom)
EH essential hypertension, NE not estimated, OR odds ratio, D expected linear increment in the trait per additional copy of the haplotype
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Importantly, we noted several limitations that should be
considered in interpreting our findings. Firstly, although we
have included age, gender and BMI in association analyses
involving blood pressure-related phenotypes, several other
covariates such as lipids and salt consumption were not
included due to the lack of information in some studies.
This statement is also valid for the risk of overweight and
BMI as a continuous variable, in which physical activity
was not available for all investigations.
Moreover, some limitations of haplotypic-based meta-
analysis are worth of consideration. For example, our meta-
analysis is based on previous published literature. Although
we enrolled six independent studies in the meta-analysis, the
number of genotyped SNPs was different across studies. As
a result, sample sizes were considerably different among
haplotypic analyses. Secondly, it is believed that haplotype-
based meta-analyses may render higher statistical power to
disclose associations of moderate to small effects [11, 29,
35]. This notion has been strongly empathized recently [36].
However, we noted several caveats when conducting a meta-
analysis of haplotype effects. The fist caveat is illustrated by
the difficulty to model effects from uncommon haplotypes.
For example, when some of the investigated variants are less
frequent in the populations, GLM models such as the one
used here may originate estimates with large uncertainty (i.e.
very large confidence intervals). Consequently, the apparent
advantage of meta-analyses of haplotype-effects may be
concealed. This occurs because even considerably high
effects from uncommon haplotypes may yield meta-analy-
ses with markedly reduced statistical power due to larger
uncertainty around point estimates. Furthermore, the con-
struction of useful models is likely to require the specifica-
tion of a threshold frequency below which uncommon
haplotypes are pooled into a single category [17]. In other
words, combination of several haplotypes into a single group
jeopardizes the interpretation and generalizability of results.
In this regard, future meta-analyses of haplotypic effects will
benefit of the development and use of new approaches for
the estimation of effects from rare haplotypes [37]. In
addition, haplotype-based analyses assume that Hardy–
Weinberg Equilibrium holds for the whole population.
Hence, the violation of theses expectations in some studies
may augment or diminish the accuracy of the estimated
haplotype frequencies [38], resulting in bias in haplotypic
effects. Finally, funnel plot and formal statistical approaches
were not employed to identify small-study biases because
the number of available studies was\10 [39].
Conclusion
Allowing for the methodological caveats, the cumulative
evidence does not support the proposal that the haplotypes
formed by common polymorphisms in the GNB3 might exert
influence on representative cardiovascular factors/pheno-
types such as hypertension, overweight, SBP, DBP and BMI.
Our results do not rule out potential GNB3 haplotypic effects
either on pharmacogenetic traits or preeclampsia.
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